JP2010540489A - 有機化合物のガレヌス製剤 - Google Patents
有機化合物のガレヌス製剤 Download PDFInfo
- Publication number
- JP2010540489A JP2010540489A JP2010526278A JP2010526278A JP2010540489A JP 2010540489 A JP2010540489 A JP 2010540489A JP 2010526278 A JP2010526278 A JP 2010526278A JP 2010526278 A JP2010526278 A JP 2010526278A JP 2010540489 A JP2010540489 A JP 2010540489A
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- pharmaceutically acceptable
- aliskiren
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 28
- 238000009472 formulation Methods 0.000 title description 11
- 239000006186 oral dosage form Substances 0.000 claims abstract description 51
- 239000007787 solid Substances 0.000 claims abstract description 41
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims abstract description 38
- 229960004601 aliskiren Drugs 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 239000003826 tablet Substances 0.000 claims description 19
- 239000000654 additive Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000012458 free base Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000004067 bulking agent Substances 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- 238000009499 grossing Methods 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 201000006370 kidney failure Diseases 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 3
- 239000008385 outer phase Substances 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 239000013543 active substance Substances 0.000 description 16
- 239000007888 film coating Substances 0.000 description 16
- 238000009501 film coating Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229910002651 NO3 Inorganic materials 0.000 description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- -1 3-amino-2,2-dimethyl-3-oxopropyl Chemical group 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000002461 renin inhibitor Substances 0.000 description 4
- 229940086526 renin-inhibitors Drugs 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 238000009490 roller compaction Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940044025 aliskiren 300 mg Drugs 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ATLUQSZJXADTHY-UHFFFAOYSA-N 5-amino-4-hydroxy-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-2,2-di(propan-2-yl)octanamide Chemical compound CC(C)C(C(=O)N)(CC(C(CCCC1=CC(=C(C=C1)OC)OCCCOC)N)O)C(C)C ATLUQSZJXADTHY-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 235000019888 Vivapur Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(a) アリスキレンまたはその薬学的に許容される塩および薬学的に許容される添加剤を混合し;
(b) 混合したアリスキレンまたはその薬学的に許容される塩および薬学的に許容される添加剤を篩い;
(c) 篩った物質を混合し;
(d) 混合した物質をローラー圧縮して圧縮された物質を形成させ;
(e) 圧縮した物質を挽いてアリスキレン顆粒と呼ぶ挽いた物質を形成させ;
(f) 所望により挽いた物質と外相、すなわち薬学的に許容される添加剤を混合して最終混合物を形成させ;
(g) 所望により最終混合物を圧縮して錠剤を形成させ、そして
(h) 所望によりフィルムコート錠を得るためにフィルムコートを適用する
工程を含む。あるいは、工程(b)および(f)を、アリスキレンまたはアリスキレン顆粒各々と平滑剤無しの添加剤との第一の混合、および第一の混合物と平滑剤との第二の(最終)混合を含む、2工程で行ってよい。
・ 相対的に高い薬剤負荷が容易に達成され得る;
・ 十分な硬度、破砕に対する抵抗性、崩壊時間などを有する薬学的経口固定投与量組み合わせ剤の製剤が可能である;
・ 医薬物質の粘着傾向および不十分な流動が最小限まで減らされる;
・ 堅牢な製造法が達成される;
・ 再現性をもたらす製剤および工程のスケールアップが達成される;および
・ 合理的な貯蔵寿命を達成するための十分な安定性が達成される。
・ 特に乾燥工程が何等存在しないため、短い処理時間が達成され、故に、より経済的である。
・ 同量の活性成分を有しながら、小さい錠剤サイズ
・ 低包装費用
・ バッチ当たり多い数の錠剤。
Claims (16)
- 治療的有効量のアリスキレン、またはその薬学的に許容される塩を含むローラー圧縮された固体経口投与形態であって、ここで、該活性成分が、該経口投与形態の総重量に基づき38重量%を超えて存在する、固体経口投与形態。
- 活性成分が40重量%を超える量で存在する、請求項1に記載の固体経口投与形態。
- 活性成分が41〜80重量%、例えば41〜60重量%の範囲の量で存在する、請求項1または2に記載の固体経口投与形態。
- 活性成分が完全にアリスキレン、またはその薬学的に許容される塩から成り、単位投与形態あたり約75〜約300mgの遊離塩基の範囲の量で存在する、請求項1〜3のいずれかに記載の固体経口投与形態。
- アリスキレンがそのヘミフマル酸塩の形態であり、単位投与形態あたり約83、約166または約332mgの量で存在する、請求項1〜4のいずれかに記載の固体経口投与形態。
- 投与形態がさらに増量剤を、該投与形態の好ましくは3〜45%重量、例えば12〜45重量%の量で含む、請求項1〜5のいずれかに記載の固体経口投与形態。
- 増量剤が微結晶性セルロース、コーンデンプンおよび/またはリン酸水素カルシウムである、請求項6に記載の固体経口投与形態。
- 投与形態がさらに崩壊剤を、該投与形態の好ましくは5〜30重量%の量で含む、請求項1〜7のいずれかに記載の固体経口投与形態。
- 投与形態がさらに平滑剤を、好ましくは該投与形態の0.5〜6重量%、例えば0.5〜4重量%の量で含む、請求項1〜8のいずれかに記載の固体経口投与形態。
- 投与形態がさらに流動促進剤を、好ましくは該投与形態の0.1〜3.0重量%、例えば0.1〜1.0重量%の量で含む、請求項1〜9のいずれかに記載の固体経口投与形態。
- 流動促進剤がコロイド状二酸化ケイ素である、請求項10に記載の固体経口投与形態。
- 高血圧、鬱血性心不全、狭心症、心筋梗塞、アテローム性動脈硬化症(artherosclerosis)、糖尿病性腎症、糖尿病性心筋症、腎不全、末梢血管疾患、左室肥大、認知機能不全、卒中、頭痛および慢性心不全の処置のための、請求項1〜11のいずれかに記載の固体経口投与形態。
- 高血圧、鬱血性心不全、狭心症、心筋梗塞、アテローム性動脈硬化症(artherosclerosis)、糖尿病性腎症、糖尿病性心筋症、腎不全、末梢血管疾患、左室肥大、認知機能不全、卒中、頭痛および慢性心不全の処置方法であって、治療的有効量の請求項1〜11のいずれかに記載の固体経口投与形態を、それを必要とする患者に投与することを含む、方法。
- 高血圧、鬱血性心不全、狭心症、心筋梗塞、アテローム性動脈硬化症(artherosclerosis)、糖尿病性腎症、糖尿病性心筋症、腎不全、末梢血管疾患、左室肥大、認知機能不全、卒中、頭痛および慢性心不全の処置用医薬の製造のための、請求項1〜11のいずれかに記載の固体経口投与形態の使用。
- アリスキレンまたはその薬学的に許容される塩および薬学的に許容される添加剤をローラー圧縮し、所望により(篩い分け後)さらなる薬学的に許容される添加剤と混合し、そして所望により最終混合物を錠剤に圧縮する、工程を含む、請求項1〜11のいずれかに記載の固体経口投与形態の製造方法。
- (a)アリスキレンまたはその薬学的に許容される塩および薬学的に許容される添加剤を混合し
(b)混合したアリスキレンまたはその薬学的に許容される塩および薬学的に許容される添加剤を篩い
(c)篩った物質を混合し
(d)混合した物質をローラー圧縮して圧縮された物質を形成させ;
(e)圧縮した物質を挽いてアリスキレン顆粒と呼ぶ挽いた物質を形成させ;
(f)所望により挽いた物質と外相、すなわち薬学的に許容される添加剤を混合して最終混合物を形成させ;
(g)所望により最終混合物を圧縮して錠剤を形成させおよび
(h)所望によりフィルムコート錠を得るためにフィルムコートを適用する
工程を含む、請求項15に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97589407P | 2007-09-28 | 2007-09-28 | |
US60/975,894 | 2007-09-28 | ||
PCT/EP2008/062769 WO2009040373A2 (en) | 2007-09-28 | 2008-09-24 | Galenical formulations of aliskiren |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010540489A true JP2010540489A (ja) | 2010-12-24 |
JP5378384B2 JP5378384B2 (ja) | 2013-12-25 |
Family
ID=40377181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010526278A Expired - Fee Related JP5378384B2 (ja) | 2007-09-28 | 2008-09-24 | 有機化合物のガレヌス製剤 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110033533A1 (ja) |
EP (2) | EP2205232A2 (ja) |
JP (1) | JP5378384B2 (ja) |
KR (1) | KR20100076996A (ja) |
CN (1) | CN101808630A (ja) |
AR (1) | AR068539A1 (ja) |
AU (1) | AU2008303504C1 (ja) |
BR (1) | BRPI0817586A2 (ja) |
CA (1) | CA2697229A1 (ja) |
CL (1) | CL2008002828A1 (ja) |
CO (1) | CO6270216A2 (ja) |
GT (1) | GT201000064A (ja) |
MA (1) | MA31768B1 (ja) |
MX (1) | MX2010003260A (ja) |
MY (1) | MY148266A (ja) |
NZ (1) | NZ584005A (ja) |
PE (1) | PE20091203A1 (ja) |
RU (1) | RU2483718C2 (ja) |
TN (1) | TN2010000120A1 (ja) |
TW (1) | TWI436760B (ja) |
WO (1) | WO2009040373A2 (ja) |
ZA (1) | ZA201001144B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2724746A1 (en) * | 2008-05-23 | 2009-11-26 | Teva Pharmaceuticals Industries Ltd. | Aliskiren monofumarate and processes for preparation thereof |
TW201136582A (en) | 2010-03-16 | 2011-11-01 | Novartis Ag | Improved pharmaceutical compositions of aliskiren and methods of delivery |
TR201002256A1 (tr) | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
EP2382969A1 (en) | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006086456A2 (en) * | 2005-02-11 | 2006-08-17 | Novartis Ag | Combination of organic compounds |
WO2006116435A2 (en) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
JP2007529456A (ja) * | 2004-03-17 | 2007-10-25 | ノバルティス アクチエンゲゼルシャフト | 有機化合物のガレヌス製剤 |
JP2009531317A (ja) * | 2006-03-21 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アリスキレンと硫酸の塩 |
JP2009531300A (ja) * | 2006-02-24 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アリスキレン硝酸塩 |
JP2009541239A (ja) * | 2006-06-23 | 2009-11-26 | ノバルティス アクチエンゲゼルシャフト | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 |
JP2010501524A (ja) * | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アリスキレン用ガレヌス製剤 |
JP2010509254A (ja) * | 2006-11-09 | 2010-03-25 | ノバルティス アーゲー | アリスキレンとオロチン酸の塩 |
JP2010540547A (ja) * | 2007-09-28 | 2010-12-24 | ノバルティス アーゲー | アリスキレンおよびバルサルタンのガレヌス製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
RU2183116C1 (ru) * | 2001-07-10 | 2002-06-10 | Жаров Олег Владимирович | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием |
US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
-
2008
- 2008-09-24 EP EP08804674A patent/EP2205232A2/en not_active Withdrawn
- 2008-09-24 CN CN200880108854A patent/CN101808630A/zh active Pending
- 2008-09-24 EP EP12188621A patent/EP2548553A1/en not_active Withdrawn
- 2008-09-24 CA CA2697229A patent/CA2697229A1/en not_active Abandoned
- 2008-09-24 PE PE2008001663A patent/PE20091203A1/es not_active Application Discontinuation
- 2008-09-24 MX MX2010003260A patent/MX2010003260A/es active IP Right Grant
- 2008-09-24 MY MYPI2010000722A patent/MY148266A/en unknown
- 2008-09-24 AR ARP080104136A patent/AR068539A1/es unknown
- 2008-09-24 KR KR1020107009195A patent/KR20100076996A/ko not_active Application Discontinuation
- 2008-09-24 CL CL2008002828A patent/CL2008002828A1/es unknown
- 2008-09-24 RU RU2010116530/15A patent/RU2483718C2/ru not_active IP Right Cessation
- 2008-09-24 TW TW097136655A patent/TWI436760B/zh not_active IP Right Cessation
- 2008-09-24 US US12/679,088 patent/US20110033533A1/en not_active Abandoned
- 2008-09-24 JP JP2010526278A patent/JP5378384B2/ja not_active Expired - Fee Related
- 2008-09-24 NZ NZ584005A patent/NZ584005A/xx not_active IP Right Cessation
- 2008-09-24 BR BRPI0817586 patent/BRPI0817586A2/pt not_active IP Right Cessation
- 2008-09-24 AU AU2008303504A patent/AU2008303504C1/en not_active Ceased
- 2008-09-24 WO PCT/EP2008/062769 patent/WO2009040373A2/en active Application Filing
-
2010
- 2010-02-17 ZA ZA2010/01144A patent/ZA201001144B/en unknown
- 2010-03-17 GT GT201000064A patent/GT201000064A/es unknown
- 2010-03-19 TN TNP2010000120A patent/TN2010000120A1/fr unknown
- 2010-04-08 MA MA32758A patent/MA31768B1/fr unknown
- 2010-04-19 CO CO10045478A patent/CO6270216A2/es not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007529456A (ja) * | 2004-03-17 | 2007-10-25 | ノバルティス アクチエンゲゼルシャフト | 有機化合物のガレヌス製剤 |
WO2006086456A2 (en) * | 2005-02-11 | 2006-08-17 | Novartis Ag | Combination of organic compounds |
WO2006116435A2 (en) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
JP2009531300A (ja) * | 2006-02-24 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アリスキレン硝酸塩 |
JP2009531317A (ja) * | 2006-03-21 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アリスキレンと硫酸の塩 |
JP2009541239A (ja) * | 2006-06-23 | 2009-11-26 | ノバルティス アクチエンゲゼルシャフト | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 |
JP2010501524A (ja) * | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アリスキレン用ガレヌス製剤 |
JP2010509254A (ja) * | 2006-11-09 | 2010-03-25 | ノバルティス アーゲー | アリスキレンとオロチン酸の塩 |
JP2010540547A (ja) * | 2007-09-28 | 2010-12-24 | ノバルティス アーゲー | アリスキレンおよびバルサルタンのガレヌス製剤 |
Also Published As
Publication number | Publication date |
---|---|
TW200922546A (en) | 2009-06-01 |
MX2010003260A (es) | 2010-04-29 |
MA31768B1 (fr) | 2010-10-01 |
JP5378384B2 (ja) | 2013-12-25 |
AU2008303504B2 (en) | 2012-03-22 |
BRPI0817586A2 (pt) | 2015-03-31 |
US20110033533A1 (en) | 2011-02-10 |
AR068539A1 (es) | 2009-11-18 |
PE20091203A1 (es) | 2009-09-11 |
KR20100076996A (ko) | 2010-07-06 |
NZ584005A (en) | 2012-08-31 |
TWI436760B (zh) | 2014-05-11 |
CN101808630A (zh) | 2010-08-18 |
CA2697229A1 (en) | 2009-04-02 |
RU2483718C2 (ru) | 2013-06-10 |
WO2009040373A2 (en) | 2009-04-02 |
WO2009040373A3 (en) | 2009-08-20 |
MY148266A (en) | 2013-03-29 |
AU2008303504C1 (en) | 2013-05-16 |
ZA201001144B (en) | 2011-12-28 |
EP2548553A1 (en) | 2013-01-23 |
CO6270216A2 (es) | 2011-04-20 |
AU2008303504A1 (en) | 2009-04-02 |
EP2205232A2 (en) | 2010-07-14 |
GT201000064A (es) | 2012-03-30 |
RU2010116530A (ru) | 2011-11-10 |
CL2008002828A1 (es) | 2009-05-15 |
TN2010000120A1 (en) | 2011-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5925607B2 (ja) | 有機化合物のガレヌス製剤 | |
JP5362556B2 (ja) | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 | |
JP5378384B2 (ja) | 有機化合物のガレヌス製剤 | |
US20110172309A1 (en) | Galenic formulations of organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130814 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130903 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130925 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |